Calls
1
Jamey Millar
Executive Vice President & Head of U.S. Operations, Novo Nordisk
Win Rate
100.0%
return
+38.4%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Apr 01
$36.36
+38.4%
Jamey Millar stated that Novo Nordisk pioneered the weight-loss drug category, with Wegovy pill achieving 17% weight loss efficacy and strong tolerability, and introduced a unique subscription model to improve adherence and affordability. These product advantages—superior efficacy, tolerability, and innovative consumer-centric pricing—are expected to sustain strong demand and market leadership, even as competitors like Eli Lilly enter the market. LONG on Novo Nordisk due to its first-mover edge, proven product performance, and strategic initiatives that enhance accessibility and patient retention in a growing market. Increased competition from Eli Lilly and other entrants, potential regulatory hurdles, adverse event reports, or shifts in consumer preference that could erode market share.
Jamey Millar stated that Novo Nordisk pioneered the weight-loss drug category, with Wegovy pill achieving 17% weight loss efficacy and strong tolerability, and introduced a unique subscription model to improve adherence and affordability. These product advantages—superior efficacy, tolerability, and innovative consumer-centric pricing—are expected to sustain strong demand and market leadership, even as competitors like Eli Lilly enter the market. LONG on Novo Nordisk due to its first-mover edge, proven product performance, and strategic initiatives that enhance accessibility and patient retention in a growing market. Increased competition from Eli Lilly and other entrants, potential regulatory hurdles, adverse event reports, or shifts in consumer preference that could erode market share.
GLP-1 / Obesity
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Jamey Millar has 1 trade ideas tracked on Buzzberg across 1 tickers since April 2026. Most covered: NVO.
